Mehran Yazdanian

2.6k total citations
32 papers, 2.1k citations indexed

About

Mehran Yazdanian is a scholar working on Pharmaceutical Science, Molecular Biology and Oncology. According to data from OpenAlex, Mehran Yazdanian has authored 32 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmaceutical Science, 8 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Mehran Yazdanian's work include Drug Transport and Resistance Mechanisms (8 papers), Drug Solubulity and Delivery Systems (6 papers) and Crystallization and Solubility Studies (5 papers). Mehran Yazdanian is often cited by papers focused on Drug Transport and Resistance Mechanisms (8 papers), Drug Solubulity and Delivery Systems (6 papers) and Crystallization and Solubility Studies (5 papers). Mehran Yazdanian collaborates with scholars based in United States, Brazil and Sweden. Mehran Yazdanian's co-authors include Kenneth L. Audus, Amale Hawi, Kimberly A. Foster, John Proudfoot, George Zografi, Hyuk Yu, Earvin Liang, Michael L. Avery, Mahn Won Kim and Erika Stippler and has published in prestigious journals such as SHILAP Revista de lepidopterología, Macromolecules and Langmuir.

In The Last Decade

Mehran Yazdanian

32 papers receiving 2.0k citations

Peers

Mehran Yazdanian

ONCOL

Isabel González‐Álvarez Spain

Salomon Stavchansky United States

Bernard Faller Switzerland

Tycho Heimbach United States

Minoru Machida Japan

Frank Senner Switzerland

Michael J. Hageman United States

William Curatolo United States

Chandrasekharan Ramachandran United States

Robert G. Strickley United States

Isabel González‐Álvarez Spain

Mehran Yazdanian

997 ×1.7

732 ×1.3

833 ×1.7

ONCOL

237 ×0.8

258 ×0.9

Citations per year, relative to Mehran Yazdanian Mehran Yazdanian (= 1×) peers Isabel González‐Álvarez

Countries citing papers authored by Mehran Yazdanian

Since Specialization

Citations

This map shows the geographic impact of Mehran Yazdanian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mehran Yazdanian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mehran Yazdanian more than expected).

Fields of papers citing papers by Mehran Yazdanian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mehran Yazdanian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mehran Yazdanian. The network helps show where Mehran Yazdanian may publish in the future.

Co-authorship network of co-authors of Mehran Yazdanian

This figure shows the co-authorship network connecting the top 25 collaborators of Mehran Yazdanian. A scholar is included among the top collaborators of Mehran Yazdanian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mehran Yazdanian. Mehran Yazdanian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yazdanian, Mehran, et al.. (2024). Magnetite MXene-Based Hybrid Platforms for Electrochemical Sensing of Anticancer Drug Idarubicin. Journal of Electronic Materials. 54(3). 1645–1652. 6 indexed citations

Landis, Margaret S., Shobha Bhattachar, Mehran Yazdanian, & J. S. Morrison. (2017). Commentary: Why Pharmaceutical Scientists in Early Drug Discovery Are Critical for Influencing the Design and Selection of Optimal Drug Candidates. AAPS PharmSciTech. 19(1). 1–10. 39 indexed citations

Bou‐Chacra, Nádia Araci, et al.. (2017). Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System. The AAPS Journal. 19(4). 989–1001. 78 indexed citations

Bergström, Christel A. S. & Mehran Yazdanian. (2016). Lipophilicity in Drug Development: Too Much or Not Enough?. The AAPS Journal. 18(5). 1095–1100. 14 indexed citations

Parr, Alan, Ismael J. Hidalgo, William E. Brown, et al.. (2015). The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers. Pharmaceutical Research. 33(1). 167–176. 55 indexed citations

Mitra, Pallabi, et al.. (2011). A Comprehensive Study Demonstrating that P-glycoprotein Function is Directly Affected by Changes in pH: Implications for Intestinal pH and Effects on Drug Absorption. Journal of Pharmaceutical Sciences. 100(10). 4258–4268. 7 indexed citations

Wells‐Knecht, Kevin J., Gregory R. Ott, Mangeng Cheng, et al.. (2011). 2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation. Chemical Research in Toxicology. 24(11). 1994–2003. 8 indexed citations

Nguyen, Loc, et al.. (2007). Is PAMPA a useful tool for discovery?. Journal of Pharmaceutical Sciences. 96(11). 2886–2892. 32 indexed citations

Young, Amber, Kenneth L. Audus, John Proudfoot, & Mehran Yazdanian. (2006). Tetrazole compounds: The effect of structure and pH on Caco-2 cell permeability. Journal of Pharmaceutical Sciences. 95(4). 717–725. 29 indexed citations

10.

Yazdanian, Mehran, et al.. (2004). The “High Solubility” Definition of the Current FDA Guidance on Biopharmaceutical Classification System May Be Too Strict for Acidic Drugs. Pharmaceutical Research. 21(2). 293–299. 237 indexed citations

11.

Hamilton, Kirk L., Mehran Yazdanian, & Kenneth L. Audus. (2002). Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics. Current Drug Metabolism. 3(1). 1–12. 14 indexed citations

12.

Yazdanian, Mehran, et al.. (2001). Modulation of P-glycoprotein activity in Calu-3 cells using steroids and β-ligands. International Journal of Pharmaceutics. 228(1-2). 171–179. 50 indexed citations

13.

Liang, Earvin, et al.. (2001). Permeability measurement of macromolecules and assessment of mucosal antigen sampling using in vitro converted M cells. Journal of Pharmacological and Toxicological Methods. 46(2). 93–101. 33 indexed citations

14.

Yazdanian, Mehran, et al.. (2001). P-glycoprotein efflux pump expression and activity in Calu-3 cells. Journal of Pharmaceutical Sciences. 90(5). 647–658. 82 indexed citations

15.

Foster, Kimberly A., Mehran Yazdanian, & Kenneth L. Audus. (2001). Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium. Journal of Pharmacy and Pharmacology. 53(1). 57–66. 167 indexed citations

16.

Liang, Earvin, John Proudfoot, & Mehran Yazdanian. (2000). Mechanisms of Transport and Structure-Permeability Relationship of Sulfasalazine and Its Analogs in Caco-2 Cell Monolayers. Pharmaceutical Research. 17(10). 1168–1174. 75 indexed citations

17.

Foster, Kimberly A., Michael L. Avery, Mehran Yazdanian, & Kenneth L. Audus. (2000). Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. International Journal of Pharmaceutics. 208(1-2). 1–11. 200 indexed citations

18.

Liang, Earvin, et al.. (2000). Evaluation of an accelerated Caco‐2 cell permeability model. Journal of Pharmaceutical Sciences. 89(3). 336–345. 63 indexed citations

19.

Yazdanian, Mehran. (1999). Blood–brain barrier properties of human immunodeficiency virus antiretrovirals. Journal of Pharmaceutical Sciences. 88(10). 950–954. 15 indexed citations

20.

Yazdanian, Mehran, et al.. (1998). Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds. Pharmaceutical Research. 15(9). 1490–1494. 379 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact